WO2010117943A1

WO2010117943A1 - Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof

Info

Publication number: WO2010117943A1
Application number: PCT/US2010/029945
Authority: WO
Inventors: Christian Lavedan; Simona Volpi; Louis Licamele
Original assignee: Vanda Pharmaceuticals, Inc.
Priority date: 2009-04-06
Filing date: 2010-04-05
Publication date: 2010-10-14
Also published as: CA2757646C; US9072742B2; US20150225795A1; US20120059035A1; US10570452B2; EP2416779A1; US20180002758A1; JP2012522839A; CA2757646A1; EP2416779B1; JP5692872B2

Abstract

The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

Description

METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION BASED ON BAI3 GENE SEQUENCE OR PRODUCT THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of co-pending US Provisional Patent Application No. 61/167,140, filed 06 April 2009, which is hereby incorporated herein.

BACKGROUND OF THE INVENTION

1. Technical Field

The invention relates generally to a method of predicting an individual's predisposition to QT prolongation, and more particularly, to a method of predicting such predisposition based on a sequence of the individual's BAI3 (brain-specific angiogenesis inhibitor 3) gene.

2. Background

Prolongation of the electrocardiographic QT interval (the time between the start of the Q wave and the end of the T wave) is referred to as long QT syndrome (LQTS). LQTS may comprise a genetic component. In some patients with LQTS, QT prolongation can be a chronic condition. In some persons, LQTS may be induced by the administration of an active pharmaceutical ingredient that prolongs the QT interval. A number of compounds are believed to be capable of prolonging the QT interval. These include amiodarone, arsenic thoxide, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, dompehdone, dropehdol, erythromycin, halofantrine, haloperidol, ibutilide, ilopehdone, levomethadyl, mesohdazine, methadone, pentamidine, pimozide, procainamide,

VAND-0046-PCT 1 quinidine, sotalol, sparfloxacin, and thioridazine.

Other compounds are suspected of being capable of prolonging the QT interval, although such prolongation has not been definitively established. These include alfuzosin, amantadine, azithromycin, chloral hydrate, clozapine, dolasetron, felbamate, flecainide, foscarnet, fosphenytoin, gatifloxacin, gemifloxacin, granisetron, indapamide, isradipine, levofloxacin, lithium, moexipril, moxifloxacin, nicardipine, octreotide, ofloxacin, ondansetron, quetiapine, ranolazine, risperidone, roxithromycin, tacrolimus, tamoxifen, telithromycin, tizanidine, vardenafil, venlafaxine, voriconazole, and ziprasidone.

Individuals at risk of suffering LQTS are advised not to use still other compounds, due to the possibility that they may prolong the QT interval. These include albuterol, amitriptyline, amoxapine, amphetamine, dextroamphetamine, atomoxetine, chloroquine, ciprofloxacin, citalopram, clomipramine, cocaine, desipramine, dexmethylphenidate, dobutamine, dopamine, doxepin, ephedrine, epinephrine, fenfluramine, fluconazole, fluoxetine, galantamine, imipramine, isoproterenol, itraconazole, ketoconazole, levalbuterol, metaproterenol, methylphenidate, mexiletine, midodrine, norepinephrine, nortriptyline, paroxetine, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ritodrine, salmeterol, sertraline, sibutramine, solifenacin, terbutaline, tolterodine, trimethoprim-sulfa, and trimipramine.

Shiratsuchi et al. mapped the BAI3 gene to 6q12 by fluorescence in situ hybridization. They found that BAI3 expression was absent in 2 of 9 glioblastoma cell lines examined and was significantly reduced in 3 of the remaining 7. These findings suggested that the gene may play an important role in suppression of

VAND-0046-PCT 2 glioblastoma. Shiratsuchi et al., Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAM ), Cytogenet. Cell Genet. 79: 103-108, 1997. PubMed ID : 9533023.

SUMMARY OF THE INVENTION

The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the diagnosis of such predisposition and for the administration of QT interval-prolonging compounds to individuals having such a predisposition.

A first aspect of the invention provides a method of administering to an individual a compound capable of prolonging the individual's QT interval, the method comprising determining at least a portion of an individual's BAI3 gene sequence; and in the case that a portion of the individual's BAI3 sequence is associated with an increased risk of QT prolongation, administering to the individual a quantity of the compound less than would be administered to an individual having a BAI3 gene sequence not associated with an increased risk of QT prolongation, or electing instead to treat the individual with a different compound not known to be associated with QT prolongation.

A second aspect of the invention provides a method of determining whether or not an individual is predisposed to prolongation of the QT interval, the method comprising: determining at least a portion of an individual's BAI3 gene sequence.

A third aspect of the invention provides a method of administering a compound capable of prolonging a QT interval to an individual suffering from long

VAND-0046-PCT 3 QT syndrome (LQTS), the method comprising: determining at least a portion of an individual's BAI3 gene sequence; and administering to the individual a quantity of the compound based on the individual's BAI3 gene sequence.

A fourth aspect of the invention provides a method of administering to an individual a compound capable of prolonging the individual's QT interval, the method comprising: characterizing an expression product of an individual's BAI3 gene; and in the case that the characterized expression product is associated with an increased risk of QT prolongation, administering to the individual a quantity of the compound less than would be administered to an individual having an expression product not associated with an increased risk of QT prolongation. Expression products of the BAI3 gene may include, for example, mRNA and protein including any isoform of the mRNA and protein.

A fifth aspect of the invention provides a method of determining whether an individual is predisposed to prolongation of the QT interval, the method comprising: characterizing an expression product of an individual's BAI3 gene.

A sixth aspect of the invention provides a method of administering a compound capable of prolonging a QT interval to an individual suffering from long QT syndrome (LQTS), the method comprising: characterizing an expression product of an individual's BAI3 gene; and administering to the individual a quantity of the compound based on the characterized expression product.

A seventh aspect of the invention provides a method of determining whether a compound is capable of prolonging QT interval in an individual, the method comprising: measuring an expression product of the individual's BAI3 gene; administering to the individual a quantity of the compound; remeasuring the

VAND-0046-PCT 4 expression product of the individual's BAI3 gene; and determining whether the compound is capable of prolonging the individual's QT interval based on a difference in the measurements of the expression product of the individual's BAI3 gene.

An eighth aspect of the invention provides a method of determining whether a compound is capable of prolonging a QT interval in an individual, the method comprising: measuring a QT interval of each of a plurality of test organisms, the plurality including a first test organism having a BAI3 genotype associated with a predisposition for prolongation of QT interval and a second organism having BAI3 genotype not associated with a predisposition for prolongation of QT interval; administering a quantity of the compound to each of the plurality of test organisms; remeasuring a QT interval of at least the first test organism; and determining that the compound is capable of prolonging a QT interval in an individual in the case that the remeasured QT interval is greater than the measured QT interval. Test organisms may include, for example, humans, animal models, and/or cell lines.

DETAILED DESCRIPTION OF THE INVENTION As indicated above, the invention provides a method of predicting an individual's predisposition to QT prolongation based on the sequence of the individual's BAI3 (brain-specific angiogenesis inhibitor 3) gene.

At least one single nucleotide polymorphisms (SNPs) within the BAI3 gene has been found to have a significant correlation to a predisposition to drug-induced QT prolongation. Table 1 , below, shows such SNPs and the genotypes associated with QT prolongation following the administration of ilopehdone.

VAND-0046-PCT TABLE 1 - BAI3 SNP Genotypes and QT Prolongation Following Administration of lloperidone

¹ Official SNP nomenclature according to NCBI db SNP version 126, May 2006.

² Chromosomal position based on the NCBI Build 36.1 , March 2006.

³ P value of genotype having highest QT values versus all other genotypes.

VAND-0046-PCT 6

VAND-0046-PCT

VAND-0046-PCT 8

VAND-0046-PCT

VAND-0046-PCT 10

VAND-0046-PCT 11

VAND-0046-PCT 12

VAND-0046-PCT 13

SNPs useful in the practice of the invention are selected from among SNPs listed in Table 1 and can be used singly or in any combination of two or more.

A genotype of GG at the rs1083338 locus was found to most accurately predict a predisposition to QT prolongation. This genotype is included amongst all genotypes associated with a predisposition to QT prolongation. Therefore, individuals having a genotype of GG at the rs1083338 locus may be considered predisposed to QT prolongation following the administration of a compound capable of prolonging the QT interval.

Since the QT interval changes with changes in heart rate, the QT interval is often measured as a corrected QT (QTc) interval. Any number of formulas may be employed to calculate the QTc, including, for example, the Fridericia formula (QTcF), the Bazett formula (QTcB), and the Rautaharju formula (QTp), among others. In the studies described herein, QT was calculated using the Fridericia formula. However,

VAND-0046-PCT 14 the present invention includes the use of any such formula or method for calculating a QTc or an uncorrected QT.

As noted above, a large number of compounds are known or suspected to be capable of inducing QT prolongation in some individuals, including individuals not suffering from LQTS. One such compound is iloperidone. llopehdone is disclosed in US Patent Nos. 5,364,866, 5,658,911 , and 6,140,345, each of which is incorporated herein by reference. Metabolites of iloperidone may also be capable of prolonging a QT interval. Metabolites of Iloperidone, e.g., 1 -[4-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3- yl)-1 -piperidinyl]propoxy]-3-methoxyphenyl]ethanol, are described in International Patent Application Publication No. WO03020707, which is also incorporated herein by reference.

Other iloperidone metabolites include: 1 -[4-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3- yl)-1 -piperidinyl]propoxy]-3-hydroxyphenyl]ethanone; 1 -[4-[3-[4-(6-Fluoro-1 ,2- benzisoxazol-3-yl)-1 -pipehdinyl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone; 4- [3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 -piperidinyl]propoxy]-3-hydroxy-αr methylbenzene methanol; 4-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 - piperidinyl]propoxyl-2-hydroxy-5-methoxy-α-methylbenzenemethanol; 1 -[4-[3-[4-(6- Fluoro-1 ,2-benzisoxazol-3-yl)-1 -piperidinyl]propoxy]-2-hydroxy-5- methoxyphenyl]ethanone; and 1 -[4-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)-1 - piperidinyl]propoxy]-2,5-dihydroxyphenyl]ethanone. See US Patent No. 5,364,866 and International Patent Application Publication Nos. WO9309276 and WO9511680, which are incorporated herein by reference.

Using the genotypes at the SNP loci above, it is possible, with a high degree of certainty, to predict an individual's predisposition to QT prolongation. Table 2

VAND-0046-PCT 15 below shows the results of a study of 174 individuals, each of whom was genotyped at the rs1083338 locus and their QT interval measured following the oral administration of 24 mg/day B. I. D. of ilopehdone for a period of two weeks.

Table 2 - QT Prolongation and Presence or Absence of a Genotype for SNP A- 1810514, rs1083338 Associated with a Predisposition to QT Prolongation

As can be seen in Table 2, an individual's BAI3 sequence at the SNP A- 1810514, rs1083338 locus is highly predictive of whether the individual will experience QT prolongation following the administration of iloperidone. For example, using the lowest threshold of a change in QTc interval (between baseline and the end of the second week) greater than 5 milliseconds (normal QTc intervals are between 0.30 and 0.44 seconds for males and between 0.30 and 0.45 for females), 39 of those individuals with the GG genotype (test is considered positive if the genotype for SNP_A-1810514, rs1083338 is GG) experienced QT prolongation while only seven such individuals did not. The resulting sensitivity (probability that the individual will have a SNP genotype associated with a predisposition to QT prolongation, given that he/she experienced QT prolongation) of 0.33, specificity

VAND-0046-PCT 16 (probability that the individual will not have a SNP genotype associated with a predisposition to QT prolongation, given that he/she did not experience QT prolongation) of 0.89, negative predictive value (probability that the individual will not experience QT prolongation, given that he/she does not have a SNP genotype associated with a predisposition to QT prolongation) of 0.43, and a positive predictive value (probability that the individual will experience QT prolongation, given that he/she has a SNP genotype associated with a predisposition to QT prolongation) of 0.85, permit one to predict with great accuracy that an individual possessing the GG genotype is likely to experience QT prolongation.

The use of higher thresholds (i.e., QTs greater than 15 and 30 milliseconds) yielded markedly increased negative predictive values (0.68 and 0.90, respectively). The associated decrease in positive predictive values, from 0.85 for QTs greater than 5 milliseconds to 0.30 for QTs greater than 30 milliseconds) suggests that additional factors affect more severe QT prolongation.

As the data in Table 2 show, an individual's BAI3 sequence at the SNP loci above may be used to predict whether an individual is predisposed to QT prolongation due to the administration of a compound capable of prolonging the QT interval. That is, individuals having a genotype of GG at the rs1083338 locus may reliably be predicted to experience a prolonged QT interval (i.e., a change in QT interval of at least 5 milliseconds) following the administration of a compound capable of prolonging the QT interval. Similarly, individuals having a genotype other than GG at the rs1083338 locus may reliably be predicted to not experience severe QT prolongation (i.e., a change in QT interval of greater than 15 milliseconds) following the administration of a compound capable of prolonging the QT interval.

VAND-0046-PCT 17 The ability to make such predictions may be used in deciding whether to treat an individual with a particular compound and/or in determining the dosage appropriate for the individual. For example, an individual predicted to experience QT prolongation may be treated with an alternative compound not known or suspected to cause QT prolongation or may be administered a lower dose of a compound capable of causing QT prolongation than would be administered to an individual not predicted to experience QT prolongation.

The present invention also includes the administration of another compound useful in treating LQTS, in addition to one or more of the compounds above. Compounds useful in treating LQTS and/or preventing cardiac events resulting from LQTS, include, for example, beta blockers, such as propranolol, nadolol, atenolol, metoprolol.

The present invention also includes the prediction of an individual's predisposition for QT prolongation based on one or more of the SNP loci above in combination with the individual's genotype or gene sequence at one or more additional genes or loci. For example, International Patent Application Publication No. WO2006039663, incorporated herein by reference, describes a method of treating an individual with a compound capable of inducing QT prolongation based on the individual's CYP2D6 genotype. Other genotypes and/or gene sequences may similarly be used in combination with the SNP loci above, including those associated with LQTS. It should also be understood that the present invention includes the characterization of an expression product of the BAI3 gene rather than, or in addition to, the determination of one or more SNP genotypes within the BAI3 gene. For example, by determining a sequence of an mRNA strand transcribed from

VAND-0046-PCT 18 the BAI3 gene, it is possible to determine the sequence of the BAI3 gene itself and, as described above, determine whether the BAI3 gene sequence is associated with a predisposition to QT prolongation.

Similarly, by properly characterizing a functional peptide or protein, including the BAI3 enzyme, translated from the mRNA strand above, it is possible to determine the sequence of the BAI3 gene itself and, as described above, determine whether the BAI3 gene sequence is associated with a predisposition to QT prolongation. In addition, the present invention includes determining whether a compound is capable of prolonging a QT interval in an individual. This may be done, for example, by measuring a change in QT interval in a test organism (e.g., human, animal model, cell line) known to possess a BAI3 genotype associated with a predisposition to QT prolongation following the administration of a quantity of compound under study.

Preferably, the compound is also administered to a test organism known to possess a BAI3 genotype not associated with a predisposition to QT prolongation. The foregoing description of various aspects of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously, many modifications and variations are possible. Such modifications and variations that may be apparent to a person skilled in the art are intended to be included within the scope of the invention as defined by the accompanying claims.

VAND-0046-PCT 19

Claims

CLAIMS What is claimed is:

1. A method of administering to an individual a compound capable of prolonging the individual's QT interval, the method comprising: determining at least a portion of an individual's BAI3 gene sequence; and in the case that a portion of the individual's BAI3 gene sequence is associated with an increased risk of QT prolongation, administering to the individual a quantity of the compound less than would be administered to an individual having a BAI3 gene sequence not associated with an increased risk of QT prolongation.

2. The method of claim 1 , wherein determining includes determining the individual's genotype at the rs1083338 locus.

3. The method of claim 2, wherein the genotype associated with an increased risk of QT prolongation is GG.

4. The method of claim 1 , further comprising: determining the individual's CYP2D6 genotype.

VAND-0046-PCT 20

5. The method of claim 1 , wherein the compound is selected from a group consisting of: amiodarone, arsenic thoxide, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofanthne, halopehdol, ibutilide, iloperidone, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, thioridazine; alfuzosin, amantadine, azithromycin, chloral hydrate, clozapine, dolasetron, felbamate, flecainide, foscarnet, fosphenytoin, gatifloxacin, gemifloxacin, granisetron, indapamide, isradipine, levofloxacin, lithium, moexipril, moxifloxacin, nicardipine, octreotide, ofloxacin, ondansetron, quetiapine, ranolazine, risperidone, roxithromycin, tacrolimus, tamoxifen, telithromycin, tizanidine, vardenafil, venlafaxine, voriconazole, ziprasidone; albuterol, amitriptyline, amoxapine, amphetamine, dextroamphetamine, atomoxetine, chloroquine, ciprofloxacin, citalopram, clomipramine, cocaine, desipramine, dexmethylphenidate, dobutamine, dopamine, doxepin, ephedrine, epinephrine, fenfluramine, fluconazole, fluoxetine, galantamine, imipramine, isoproterenol, itraconazole, ketoconazole, levalbuterol, metaproterenol, methylphenidate, mexiletine, midodrine, norepinephrine, nortriptyline, paroxetine, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ritodrine, salmeterol, sertraline, sibutramine, solifenacin, terbutaline, tolterodine, trimethoprim-sulfa, trimipramine, and metabolites, pharmaceutically-acceptable salts, and combinations thereof.

VAND-0046-PCT 21

6. The method of claim 5, wherein the compound has the formula:

wherein:

R is, independently, hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, lower hydroxyketone, lower alkanol, hydroxyl acetic acid, pyruvic acid, ethanediol, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, thfluoromethoxy, cyano, acylamino, thfluoromethyl, thfluoroacetyl, aminocarbonyl, monoaklylaminocarbonyl, dialkylaminocarbonyl, formyl,

O O O

C — aikyi C - O - aikyt aryl — C — heteroaryt

OR- W W W alkyl - C -- alky! aryl C heteroaryt or alkyl is lower alkyl, branched or straight and saturated or unsaturated; acyl is lower alkyl or lower alkyloxy bonded through a carbonyl; aryl is phenyl or phenyl substituted with at least one group, R₅, wherein each R₅ is, independently, hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is is a five- or six-membered aryl ring having at least one

VAND-0046-PCT 22 heteroatom, Q₃, wherein each Q₃ is, independently, -O-, -S-, -N(H)-, or -C(H)=N-

W is CH₂ or CHR₈ or N-R₉;

Ri is -H, lower alkyl, -OH, halo, lower alkoxy, trifluormethyl, nitro, or amino;

R₂ is C₂-C₅ alkylene, alkenylene (cis or trans), or alkynylene, optionally substituted by at least one d-C₆ linear alkyl group, phenyl group or

lower alkyleny!

where Z^ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂, or halogen;

R₃ is lower alkyl or hydrogen;

R₇ is hydrogen, lower alkyl, or acyl;

R₈ is lower alkyl;

R₉ is hydroxy, lower alkoxy, or -NHRi₀;

Rio is hydrogen, lower alkyl, Ci-C₃ acyl, aryl,

O O

— C — aryl — C — heteroaryi or ;

Xi, X₂, and X₃are, independently, -O-, -S-, =N-, Or -N(R₃)-, or Xi and X₂ are not covalently bound to each other and are, independently, -OH, =0, -R₃, or =NR₃; lower is 1 -4 carbon atoms; m is 1 , 2, or 3; and n is 1 or 2.

VAND-0046-PCT 23

7. The method of claim 6, wherein:

R is -C(O)CH₂OH, -CH(OH)C(O)CH₂OH, -C(O)OH, CH(OH)CH₃, or C(O)CH₃;

Ri is halo;

Xi and X₂ are different and are =0, -OH, =N-, or -O-;

R₂ is C₂-C₄ alkylene or alkenylene;

R₃ is hydrogen, methyl, or ethyl;

X₃ is -O-;

R is

8. The method of claim 7, wherein the compound of Formula 1 is 1 -[4-3-[4-(6- fluoro-1 ,2-benzisoxazol-3-yl)-1 -pipehdinyl]propoxy]-3-methoxyphenyl]ethanone, as shown in Formula 1 B:

VAND-0046-PCT 24

9. The method of claim 7, wherein the compound of Formula 1 is 1-[4-[3-[4-(6- Fluoro-1 ,2-benzisoxazol-3-yl)-1 -piperidinyl]propoxy]-3-methoxyphenyl]ethanol, as shown in Formula 1 C:

10. A method of determining whether an individual is predisposed to prolongation of the QT interval, the method comprising: determining at least a portion of an individual's BAI3 gene sequence.

11. The method of claim 10, further comprising: in the case that a portion of the individual's BAI3 gene sequence is associated with an increased risk of QT prolongation, administering to the individual a compound not known or suspected to cause QT prolongation.

12. The method of claim 10, wherein determining includes determining the individual's genotype at the rs1083338 locus.

13. The method of claim 12, wherein the genotype associated with an increased risk of QT prolongation is GG.

VAND-0046-PCT 25

14. The method of claim 10, further comprising: determining the individual's CYP2D6 genotype.

15. A method of administering a compound capable of prolonging a QT interval to an individual suffering from long QT syndrome (LQTS), the method comprising: determining at least a portion of an individual's BAI3 gene sequence; and administering to the individual a quantity of the compound based on the individual's BAI3 gene sequence.

16. The method of claim 15, wherein determining includes determining the individual's genotype at the rs1083338 locus.

17. The method of claim 16, wherein the genotype associated with an increased risk of QT prolongation is GG.

18. The method of claim 15, further comprising: determining the individual's CYP2D6 genotype.

19. The method of claim 15, wherein the compound is selected from a group consisting of: amiodarone, arsenic thoxide, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofanthne, halopehdol, ibutilide, iloperidone, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin,

VAND-0046-PCT 26 thioridazine; alfuzosin, amantadine, azithromycin, chloral hydrate, clozapine, dolasetron, felbamate, flecainide, foscarnet, fosphenytoin, gatifloxacin, gemifloxacin, granisetron, indapamide, isradipine, levofloxacin, lithium, moexipril, moxifloxacin, nicardipine, octreotide, ofloxacin, ondansetron, quetiapine, ranolazine, risperidone, roxithromycin, tacrolimus, tamoxifen, telithromycin, tizanidine, vardenafil, venlafaxine, voriconazole, ziprasidone; albuterol, amitriptyline, amoxapine, amphetamine, dextroamphetamine, atomoxetine, chloroquine, ciprofloxacin, citalopram, clomipramine, cocaine, desipramine, dexmethylphenidate, dobutamine, dopamine, doxepin, ephedrine, epinephrine, fenfluramine, fluconazole, fluoxetine, galantamine, imipramine, isoproterenol, itraconazole, ketoconazole, levalbuterol, metaproterenol, methylphenidate, mexiletine, midodrine, norepinephrine, nortriptyline, paroxetine, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ritodrine, salmeterol, sertraline, sibutramine, solifenacin, terbutaline, tolterodine, trimethoprim-sulfa, trimipramine, and metabolites, pharmaceutically-acceptable salts, and combinations thereof.

20. The method of claim 19, wherein the compound has the formula:

wherein:

VAND-0046-PCT 27 R is, independently, hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, lower hydroxyketone, lower alkanol, hydroxyl acetic acid, pyruvic acid, ethanediol, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, thfluoromethoxy, cyano, acylamino, thfluoromethyl, thfluoroacetyl, aminocarbonyl, monoaklylaminocarbonyl, dialkylaminocarbonyl, formyl,

O C ) C ) C 3

Q aikyi - : - O - aikyt — C - aryl — C heteroaryt

— heteroaryt

alkyl is lower alkyl, branched or straight and saturated or unsaturated; acyl is lower alkyl or lower alkyloxy bonded through a carbonyl; aryl is phenyl or phenyl substituted with at least one group, R₅, wherein each R₅ is, independently, hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; heteroaryl is is a five- or six-membered aryl ring having at least one heteroatom, Q₃, wherein each Q₃ is, independently, -O-, -S-, -N(H)-, or -C(H)=N-

W is CH₂ or CHR₈ or N-R₉;

lower alkylenyl

VAND-0046-PCT 28 where Zi is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂, or halogen; R₃ is lower alkyl or hydrogen; R₇ is hydrogen, lower alkyl, or acyl; R₈ is lower alkyl;

R₉ is hydroxy, lower alkoxy, or -NHRi₀; Rio is hydrogen, lower alkyl, Ci-C₃ acyl, aryl,

O O

w Cti y I w ^■-^■-^■-^■~ i IcI¹Ci Uαl y \ or ;

21. The method of claim 20, wherein:

R is -C(O)CH₂OH, -CH(OH)C(O)CH₂OH, -C(O)OH, CH(OH)CH₃, or C(O)CH₃;

Ri is halo;

Xi and X₂ are different and are =0, -OH, =N-, or -O-;

R₂ is C₂-C₄ alkylene or alkenylene;

R₃ is hydrogen, methyl, or ethyl;

X₃ is -O-;

R is

VAND-0046-PCT 29

22. The method of claim 21 , wherein the compound of Formula 1 is 1 -[4-3-[4-(6- fluoro-1 ,2-benzisoxazol-3-yl)-1 -pipehdinyl]propoxy]-3-methoxyphenyl]ethanone, as shown in Formula 1 B:

23. The method of claim 21 , wherein the compound of Formula 1 is 1 -[4-[3-[4-(6- Fluoro-1 ,2-benzisoxazol-3-yl)-1 -piperidinyl]propoxy]-3-methoxyphenyl]ethanol, as shown in Formula 1 C:

VAND-0046-PCT 30

24. A method of administering to an individual a compound capable of prolonging the individual's QT interval, the method comprising: characterizing an expression product of an individual's BAI3 gene; and in the case that the characterized expression product is associated with an increased risk of QT prolongation, administering to the individual a quantity of the compound less than would be administered to an individual having an expression product not associated with an increased risk of QT prolongation.

25. The method of claim 24, wherein the expression product includes at least one expression product selected from a group consisting of: mRNA, a peptide, and a protein.

26. A method of determining whether an individual is predisposed to prolongation of the QT interval, the method comprising: characterizing an expression product of an individual's BAI3 gene.

27. The method of claim 26, wherein the expression product includes at least one expression product selected from a group consisting of: mRNA, a peptide, and a protein.

28. A method of administering a compound capable of prolonging a QT interval to an individual suffering from long QT syndrome (LQTS), the method comprising: characterizing an expression product of an individual's BAI3 gene; and administering to the individual a quantity of the compound based on the

VAND-0046-PCT 31 characterized expression product.

29. The method of claim 28, wherein the expression product includes at least one expression product selected from a group consisting of: mRNA, a peptide, and a protein.

30. A method of determining whether a compound is capable of prolonging a QT interval in an individual, the method comprising: measuring an expression product of the individual's BAI3 gene; administering to the individual a quantity of the compound; remeasuring the expression product of the individual's BAI3 gene; and determining whether the compound is capable of prolonging the individual's QT interval based on a difference in the measurements of the expression product of the individual's BAI3 gene.

31. The method of claim 30, wherein the expression product includes at least one expression product selected from a group consisting of: mRNA, a peptide, and a protein.

32. A method of determining whether a compound is capable of prolonging a QT interval in an individual, the method comprising: measuring a QT interval of each of a plurality of test organisms, the plurality including a first test organism having a BAI3 genotype associated with a predisposition for prolongation of QT interval and a second organism having a BAI3

VAND-0046-PCT 32 genotype not associated with a predisposition for prolongation of QT interval; administering a quantity of the compound to each of the plurality of test organisms; remeasuring a QT interval of at least the first test organism; and determining that the compound is capable of prolonging a QT interval in an individual in the case that the remeasured QT interval is greater than the measured

QT interval.

33. The method of claim 32, wherein each of the plurality of test organisms is selected from a group consisting of: humans, animals, and cell lines.

VAND-0046-PCT 33